CN108904763A - Composition and its preparation method and application containing compound lactobacillus - Google Patents
Composition and its preparation method and application containing compound lactobacillus Download PDFInfo
- Publication number
- CN108904763A CN108904763A CN201811125513.XA CN201811125513A CN108904763A CN 108904763 A CN108904763 A CN 108904763A CN 201811125513 A CN201811125513 A CN 201811125513A CN 108904763 A CN108904763 A CN 108904763A
- Authority
- CN
- China
- Prior art keywords
- compound lactobacillus
- containing compound
- lactobacillus
- composition
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 91
- 241000186660 Lactobacillus Species 0.000 title claims abstract description 88
- 229940039696 lactobacillus Drugs 0.000 title claims abstract description 88
- 239000000203 mixture Substances 0.000 title claims abstract description 60
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- 239000002994 raw material Substances 0.000 claims abstract description 24
- 230000000968 intestinal effect Effects 0.000 claims abstract description 22
- 231100000753 hepatic injury Toxicity 0.000 claims abstract description 20
- 230000001476 alcoholic effect Effects 0.000 claims abstract description 16
- 235000013406 prebiotics Nutrition 0.000 claims abstract description 15
- 206010067125 Liver injury Diseases 0.000 claims abstract description 14
- 230000002757 inflammatory effect Effects 0.000 claims abstract description 13
- 240000002605 Lactobacillus helveticus Species 0.000 claims abstract description 8
- 235000013967 Lactobacillus helveticus Nutrition 0.000 claims abstract description 8
- 229940054346 lactobacillus helveticus Drugs 0.000 claims abstract description 8
- 241001608472 Bifidobacterium longum Species 0.000 claims abstract description 7
- 240000006024 Lactobacillus plantarum Species 0.000 claims abstract description 7
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims abstract description 7
- 229940009291 bifidobacterium longum Drugs 0.000 claims abstract description 7
- 229940072205 lactobacillus plantarum Drugs 0.000 claims abstract description 7
- 235000013305 food Nutrition 0.000 claims description 16
- 238000012216 screening Methods 0.000 claims description 15
- 239000000832 lactitol Substances 0.000 claims description 8
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 claims description 8
- 229960003451 lactitol Drugs 0.000 claims description 8
- 235000010448 lactitol Nutrition 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 7
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims description 6
- 150000003271 galactooligosaccharides Chemical class 0.000 claims description 6
- 238000007873 sieving Methods 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 5
- 239000007910 chewable tablet Substances 0.000 claims description 4
- 239000007937 lozenge Substances 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims 1
- 238000001035 drying Methods 0.000 claims 1
- 244000163122 Curcuma domestica Species 0.000 abstract description 9
- 235000003392 Curcuma domestica Nutrition 0.000 abstract description 9
- 235000003373 curcuma longa Nutrition 0.000 abstract description 9
- 235000013976 turmeric Nutrition 0.000 abstract description 9
- 230000002265 prevention Effects 0.000 abstract description 8
- 150000004676 glycans Chemical class 0.000 abstract description 7
- 229920001282 polysaccharide Polymers 0.000 abstract description 7
- 239000005017 polysaccharide Substances 0.000 abstract description 7
- 241001506047 Tremella Species 0.000 abstract description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 abstract description 4
- 238000009826 distribution Methods 0.000 abstract description 3
- 229920001542 oligosaccharide Polymers 0.000 abstract description 3
- 150000002482 oligosaccharides Chemical class 0.000 abstract description 3
- 239000004310 lactic acid Substances 0.000 abstract description 2
- 235000014655 lactic acid Nutrition 0.000 abstract description 2
- 229920001661 Chitosan Polymers 0.000 abstract 1
- 230000000052 comparative effect Effects 0.000 description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 22
- 230000000694 effects Effects 0.000 description 16
- 210000004185 liver Anatomy 0.000 description 16
- 210000001035 gastrointestinal tract Anatomy 0.000 description 12
- 210000000936 intestine Anatomy 0.000 description 11
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 10
- 241000700159 Rattus Species 0.000 description 9
- 241000894006 Bacteria Species 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 238000011049 filling Methods 0.000 description 8
- 230000003110 anti-inflammatory effect Effects 0.000 description 7
- 230000004888 barrier function Effects 0.000 description 7
- 230000006378 damage Effects 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 101710105284 Sialin Proteins 0.000 description 5
- 244000052616 bacterial pathogen Species 0.000 description 5
- 235000012000 cholesterol Nutrition 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 230000037356 lipid metabolism Effects 0.000 description 5
- 239000002504 physiological saline solution Substances 0.000 description 5
- 230000000770 proinflammatory effect Effects 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 102000004889 Interleukin-6 Human genes 0.000 description 4
- 108090001005 Interleukin-6 Proteins 0.000 description 4
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 4
- 208000007107 Stomach Ulcer Diseases 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 238000009395 breeding Methods 0.000 description 4
- 230000001488 breeding effect Effects 0.000 description 4
- RQFQJYYMBWVMQG-IXDPLRRUSA-N chitotriose Chemical compound O[C@@H]1[C@@H](N)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](N)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)[C@@H](CO)O1 RQFQJYYMBWVMQG-IXDPLRRUSA-N 0.000 description 4
- 201000005917 gastric ulcer Diseases 0.000 description 4
- 230000002440 hepatic effect Effects 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 230000035764 nutrition Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 208000007848 Alcoholism Diseases 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 240000006053 Garcinia mangostana Species 0.000 description 3
- 235000017048 Garcinia mangostana Nutrition 0.000 description 3
- 206010019837 Hepatocellular injury Diseases 0.000 description 3
- 102100037850 Interferon gamma Human genes 0.000 description 3
- 108010074328 Interferon-gamma Proteins 0.000 description 3
- 102000003777 Interleukin-1 beta Human genes 0.000 description 3
- 108090000193 Interleukin-1 beta Proteins 0.000 description 3
- 102000004125 Interleukin-1alpha Human genes 0.000 description 3
- 108010082786 Interleukin-1alpha Proteins 0.000 description 3
- 108090000340 Transaminases Proteins 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 230000001133 acceleration Effects 0.000 description 3
- 201000007930 alcohol dependence Diseases 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 231100000437 hepatocellular injury Toxicity 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 210000004400 mucous membrane Anatomy 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 230000001502 supplementing effect Effects 0.000 description 3
- 102000014898 transaminase activity proteins Human genes 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
- 108010082126 Alanine transaminase Proteins 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000005482 chemotactic factor Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000003859 lipid peroxidation Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 206010016262 Fatty liver alcoholic Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 101000685693 Mus musculus Sialin Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- FHKPLLOSJHHKNU-INIZCTEOSA-N [(3S)-3-[8-(1-ethyl-5-methylpyrazol-4-yl)-9-methylpurin-6-yl]oxypyrrolidin-1-yl]-(oxan-4-yl)methanone Chemical compound C(C)N1N=CC(=C1C)C=1N(C2=NC=NC(=C2N=1)O[C@@H]1CN(CC1)C(=O)C1CCOCC1)C FHKPLLOSJHHKNU-INIZCTEOSA-N 0.000 description 1
- JAWMENYCRQKKJY-UHFFFAOYSA-N [3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-ylmethyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-en-8-yl]-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]methanone Chemical compound N1N=NC=2CN(CCC=21)CC1=NOC2(C1)CCN(CC2)C(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F JAWMENYCRQKKJY-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000026594 alcoholic fatty liver disease Diseases 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229940099352 cholate Drugs 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000007413 intestinal health Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 230000003870 intestinal permeability Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- -1 lipid peroxide Chemical class 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 208000018191 liver inflammation Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000009854 mucosal lesion Effects 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 235000016236 parenteral nutrition Nutrition 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/20—Agglomerating; Granulating; Tabletting
- A23P10/28—Tabletting; Making food bars by compression of a dry powdered mixture
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Microbiology (AREA)
- Nutrition Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention provides a kind of composition and its preparation method and application containing compound lactobacillus.Wherein, a kind of composition containing compound lactobacillus, the raw material components including following parts by weight：4-10 parts of compound lactic acid, 0.1-1 parts of tremella polysaccharides, 2-8 parts of chitosan oligosaccharides, 1-5 portions of turmerics and 45-110 parts of prebiotics, the compound lactobacillus include Lactobacillus helveticus, lactobacillus plantarum and bifidobacterium longum.The above-mentioned composition each group distribution ratio containing compound lactobacillus is reasonable, the optimal efficacy of composition can be played, there are prevention and/or treatment to alcoholic liver injury, in addition, the composition containing compound lactobacillus also plays the role of significantly preventing and/or treating to intestinal inflammatory.
Description
Technical field
The present invention relates to field of functional food, and in particular to a kind of containing the composition of compound lactobacillus and its preparation side
Method and application.
Background technique
Increase with the development of economy with social activity, drinking has become friend's party and work dinner party is essential
Link, the health of people and long-term Ethanol intake is slowly overdrawed, long-term alcohol can make each organ of body
At damage, mucosal lesion can be caused to cause gastric ulcer even bleeding threat to life, it is also possible to lead to Fat Accumulation in liver, lure
Send out the diseases such as alcoholic fatty liver.Since the intake intracorporal alcohol of people is mainly in liver intracellular metabolite, so long-term alcohol or excess
It drinks most obvious to the damage of liver, most easily induces alcoholic liver injury.
In addition, that some researches show that alcoholic liver injuries is related to the function of enteron aisle or structure disturbance, between enteron aisle and liver
In the presence of the access adjusted mutually, referred to as intestines-liver axis.The performance of intestines-liver axis best-of-breed functionality state depends on intestinal health, tool
For body, the change of intestinal microecology will affect cholate synthesis and bile acid biosynthesis, lead to lipid and energetic supersession access disorder,
It is deposited in liver so as to cause lipid peroxide and fatty acid, eventually leads to liver diseases.And alcohol will lead to greatly
The quantity of the small enteral Bacillus acidi lactici of mouse and Bifidobacterium significantly reduces, and the conditioned pathogens such as enterococcus and enterobacteria then obviously increase
Add, the disorder meeting of intestinal flora is so that Parenteral Nutrition metabolism gets muddled, protein, carbohydrate and vitamin
Digestion and absorption are affected.In addition, the intestinal flora of disorder can damage intestinal mucosa, the barrier between enteron aisle and blood is complete
Property can be destroyed, intestinal permeability increase, cause bacterium and its metabolin to enter the circulatory system, bacterium and its product promote work
The generation of property oxygen molecule, pro-inflammatory cytokine and chemotactic factor (CF), has been further exacerbated by the hair of hepatocellular injury and hepar damnification
It is raw.
Furthermore alcohol also results in the increase of Gram-negative bacteria in enteric bacteria, it will lead to endotoxin and largely discharged
Out, exceed the Scavenging activity of liver, endotoxin can also be identified by the immunocyte in liver causes a series of be immunized instead
It answers, and then causes hepatic injury.
The above results illustrate that the immunocyte in the stable state of intestinal flora, the complete of gut barrier and liver is to Alcoholic
Hepatic injury plays an important role.
Summary of the invention
Based on this, it is necessary to which aiming at the problem that alcoholic liver injury, providing one kind has prevention and/or treatment alcoholic liver
The composition and its preparation method and application containing compound lactobacillus of damage.
A kind of composition containing compound lactobacillus, the raw material components including following parts by weight：
Wherein, the compound lactobacillus includes Lactobacillus helveticus, lactobacillus plantarum and bifidobacterium longum.
The above-mentioned composition each group distribution ratio containing compound lactobacillus is reasonable, the optimal efficacy of composition can be played, to wine
Essence hepatic injury plays the role of prevention and/or treatment, in addition, the composition containing compound lactobacillus also has significantly intestinal inflammatory
The effect of prevention and/or treatment.Specifically, compound lactobacillus, is mainly used for supplementing beneficial bacteria of intestinal tract, inhibits pathogenic bacteria in intestines
Adherency in road protects gut barrier and prevents intestines from leaking.Turmeric is conducive to anti-inflammatory, and turmeric can also be by raising peroxidating
Hydrogen enzyme, and then the hydrolysis of acceleration of alcohol.And the film forming of tremella polysaccharides is strong, it being capable of effective renovating tummy mucous membrane, alleviation gastric ulcer.Shell
Oligosaccharides is conducive to anti-inflammatory, protection gastrointestinal tract, relieving alcoholism and protecting liver.Prebiotics are conducive to adjust the balanced growth of intestinal flora, change
Kind functions of intestines and stomach, prebiotics can also provide nutrition in the intracorporal breeding of people for compound lactobacillus.
The viable count contained in the compound lactobacillus in one of the embodiments, is 2.0 × 1010-1.0×
1011CFU/g。
The prebiotics are selected from one of oligofructose, galactooligosaccharide and lactitol in one of the embodiments,
Or it is several.
In one of the embodiments, the prebiotics be the oligofructose of 10-30 parts by weight, 20-40 parts by weight it is low
The combination of poly- galactolipin and the lactitol of 15-40 parts by weight.
The present invention also provides a kind of preparation methods of composition containing compound lactobacillus of the present invention.
A kind of preparation method of the composition of the present invention containing compound lactobacillus, includes the following steps：
Each raw material is taken according to corresponding parts by weight；
Other each raw materials in addition to compound lactobacillus are sieved respectively and obtain screening object；
The screening object and compound lactobacillus are mixed.
The preparation method of composition containing compound lactobacillus is simple, easy to operate, is suitble to industrialized production.
The sieving referred to 50-70 mesh in one of the embodiments, and interception partial size is less than the screening of 50-70 mesh
Object.
In one of the embodiments, before sieving, further include by other each raw materials in addition to compound lactobacillus 50 DEG C-
It is dry at 70 DEG C, until the moisture content in each raw material is lower than 3%.
The present invention also provides a kind of food.
A kind of food comprising acceptable auxiliary material on the composition and food of the present invention containing compound lactobacillus.
Above-mentioned food has the function of preventing and treating alcoholic liver injury.In addition, above-mentioned food also has intestinal inflammatory
The effect significantly prevented and treated.
The type of the food is lozenge, chewable tablets or solid beverage in one of the embodiments,.
The present invention also provides a kind of composition containing compound lactobacillus as described in the present invention preparation for preventing and/or
Treat the application in the drug of alcoholic liver injury or intestinal inflammatory.
A kind of composition according to the present invention containing compound lactobacillus is in preparation for preventing and/or treating Alcoholic
Application in the drug of hepatic injury or intestinal inflammatory.
The above-mentioned composition containing compound lactobacillus is added in drug, can play prevention and/or treatment alcoholic liver injury
Or the effect of intestinal inflammatory.
Specific embodiment
In order to make the foregoing objectives, features and advantages of the present invention clearer and more comprehensible, below in conjunction with specific embodiment,
The present invention will be described in further detail.It should be appreciated that the specific embodiments described herein are only used to explain this hair
It is bright, it is not intended to limit the present invention.
Unless otherwise defined, all technical and scientific terms used herein and belong to technical field of the invention
The normally understood meaning of technical staff is identical.Term as used herein in the specification of the present invention is intended merely to description tool
The purpose of the embodiment of body, it is not intended that in the limitation present invention.
Raw materials used and reagent is commercially available common raw material and reagent unless otherwise specified in following embodiment.
The present invention provides a kind of composition containing compound lactobacillus comprising the raw material components of following parts by weight：
The compound lactobacillus includes Lactobacillus helveticus, lactobacillus plantarum and bifidobacterium longum.
Wherein, compound lactobacillus is mainly used for supplementing beneficial bacteria of intestinal tract, inhibits adherency of the pathogenic bacteria in enteron aisle, protection
Gut barrier simultaneously prevents intestines from leaking.
In a preferred embodiment, compound lactobacillus is by Lactobacillus helveticus R52, lactobacillus plantarum R1012 and long bifid
Bacillus R175 is mixed, and inventor cooperates these three bacterial strains, is more advantageous to and is maintained intestinal microecology balance, thus logical
The effect of intestines liver axis is crossed to prevent alcoholic liver injury.
In a preferred embodiment, compound lactobacillus by 2-4 parts by weight Lactobacillus helveticus, 0.5-2 parts by weight plant
Object lactobacillus and the bifidobacterium longum of 1.5-4 parts by weight mix.
In a preferred embodiment, the viable count contained in the composition containing compound lactobacillus is 2.0 × 1010-
1.0×1011CFU/g.It is more advantageous to compound lactobacillus and plays the best use, inhibit enteric bacterial pathogens growth, protection gut barrier is simultaneously
Prevent intestines from leaking.
In a preferred embodiment, the viable count contained in the composition of contained compound lactobacillus is 5.0 × 1010-7.0
×1010CFU/g.It is more advantageous to compound lactobacillus and plays the best use, inhibit enteric bacterial pathogens growth, protect gut barrier and prevent
Intestines leakage.
Wherein, turmeric is mainly used for anti-inflammatory, can also be by raising catalase, and then the water of acceleration of alcohol
Solution.
Wherein, the film forming of tremella polysaccharides is strong, being capable of effective renovating tummy mucous membrane, alleviation gastric ulcer.
Wherein, chitosan oligosaccharide is conducive to anti-inflammatory, protection gastrointestinal tract, relieving alcoholism and protecting liver.
Wherein, prebiotics are conducive to adjust the balanced growth of intestinal flora, improve functions of intestines and stomach, can also be compound lactic acid
Bacterium provides nutrition in the intracorporal breeding of people.
In a preferred embodiment, the prebiotics are selected from one of oligofructose, galactooligosaccharide and lactitol
Or it is several.It is highly preferred that the prebiotics are selected from oligofructose, galactooligosaccharide and three kinds of lactitol of combination.And then more have
Nutrition is provided in the intracorporal breeding of people conducive to the balanced growth for adjusting intestinal flora and for compound lactobacillus.
In a preferred embodiment, the prebiotics be the oligofructose of 10-30 parts by weight, 20-40 parts by weight it is low
The combination of poly- galactolipin and the lactitol of 15-40 parts by weight.
In a preferred embodiment, the above-mentioned composition containing compound lactobacillus further includes mangosteen powder, to enhance the group
The sweet taste of object is closed, and then improves the mouthfeel of composition.
In a preferred embodiment, a kind of composition containing compound lactobacillus includes the raw material components of following parts by weight：
Wherein the compound lactobacillus be the Lactobacillus helveticus of 2-4 parts by weight, 0.5-2 parts by weight lactobacillus plantarum and
The bifidobacterium longum of 1.5-4 parts by weight mixes.
In a preferred embodiment, a kind of composition containing compound lactobacillus includes the raw material components of following parts by weight：
The above-mentioned composition each group distribution ratio containing compound lactobacillus is reasonable, the optimal efficacy of composition can be played, to wine
Essence hepatic injury plays the role of prevention and/or treatment, in addition, the composition containing compound lactobacillus also has significantly intestinal inflammatory
The effect of prevention and/or treatment.Specifically, compound lactobacillus, is mainly used for supplementing beneficial bacteria of intestinal tract, inhibits pathogenic bacteria in intestines
Adherency in road protects gut barrier and prevents intestines from leaking.Turmeric is conducive to anti-inflammatory, and turmeric can also be by raising peroxidating
Hydrogen enzyme, and then the hydrolysis of acceleration of alcohol.And the film forming of tremella polysaccharides is strong, it being capable of effective renovating tummy mucous membrane, alleviation gastric ulcer.Shell
Oligosaccharides is conducive to anti-inflammatory, protection gastrointestinal tract, relieving alcoholism and protecting liver.Prebiotics are conducive to adjust the balanced growth of intestinal flora, change
Kind functions of intestines and stomach, prebiotics can also provide nutrition in the intracorporal breeding of people for compound lactobacillus.
The present invention also provides a kind of preparation methods of composition containing compound lactobacillus.
A kind of preparation method of the composition containing compound lactobacillus, includes the following steps：
S1, each raw material is taken according to corresponding parts by weight.
S2, other each raw materials in addition to compound lactobacillus are sieved respectively obtains screening object.Wherein, screening object can be silver
The combination of fungus polysaccharides, chitosan oligosaccharide, turmeric and prebiotics, screening object be also possible to tremella polysaccharides, chitosan oligosaccharide, turmeric, prebiotics and
The combination of mangosteen powder.Wherein, the compound lactobacillus includes Lactobacillus helveticus, lactobacillus plantarum and bifidobacterium longum.
S3, the screening object and compound lactobacillus are mixed.
In a preferred embodiment, the sieving referred to 50-70 mesh, and interception partial size is less than the screening of 50-70 mesh
Object.Such benefit is to make the composition exquisiteness containing compound lactobacillus uniformly, and mouthfeel is more excellent.
In a preferred embodiment, before sieving, further include by other each raw materials in addition to compound lactobacillus 50 DEG C-
It is dry at 70 DEG C, until the moisture content in each raw material is lower than 3%.Such benefit is so that the reduction of product water activity, guarantees
The Food Shelf-life of strain activity and the composition with extension comprising compound lactobacillus.
The preparation method of composition containing compound lactobacillus is simple, easy to operate, is suitble to industrialized production.
The present invention also provides a kind of food.It includes as described in the present invention on composition and food containing compound lactobacillus
Acceptable auxiliary material.
In a preferred embodiment, the auxiliary material is food additives, such as sweetener, antioxidant.
In a preferred embodiment, the type of the food is lozenge, chewable tablets or solid beverage.
Lozenge, chewable tablets or solid beverage are prepared into using common process known to those skilled in the art, herein no longer
It repeats.
Above-mentioned food has the function of preventing and treating alcoholic liver injury.In addition, above-mentioned food also has intestinal inflammatory
The effect significantly prevented and treated.
The present invention also provides a kind of composition containing compound lactobacillus as described in the present invention preparation for preventing and/or
Treat the application in the drug of alcoholic liver injury or intestinal inflammatory.
A kind of composition containing compound lactobacillus as described in the present invention is in preparation for preventing and/or treating alcoholic liver
Application in the drug of damage or intestinal inflammatory.
The above-mentioned composition containing compound lactobacillus is added in drug, can play prevention and/or treatment alcoholic liver injury
Or the effect of intestinal inflammatory.
It is described in detail below with reference to specific embodiment.
Embodiment
The raw material components of composition of the present invention containing compound lactobacillus are weighed by the parts by weight in table 1：
Table 1
Then the raw material by above-mentioned in addition to compound lactobacillus is dried to its moisture content under the conditions of 60 DEG C be lower than respectively
3%, it crosses 60 meshes and obtains screening object, it then will screening object and compound mixing.The group containing compound lactobacillus being finally prepared
Close object.
Comparative example
The raw material components of composition of the present invention containing compound lactobacillus are weighed by the parts by weight in table 2：
Table 2
| Comparative example 1 | Comparative example 2 | Comparative example 3 | |
| Compound lactobacillus | 20 | 0 | 0 |
| Tremella polysaccharides | 0 | 10 | 0 |
| Chitosan oligosaccharide | 0 | 10 | 10 |
| Turmeric | 0 | 0 | 10 |
| Oligofructose | 24 | 20.5 | 30 |
| Galactooligosaccharide | 24 | 33.5 | 30 |
| Lactitol | 24 | 24 | 24 |
| Mangosteen powder | 2 | 2 | 2 |
Then the raw material by above-mentioned in addition to compound lactobacillus is dried to its moisture content under the conditions of 60 DEG C be lower than respectively
3%, it crosses 60 meshes and obtains screening object, it then will screening object and compound mixing.The group containing compound lactobacillus being finally prepared
Close object.
Effect assessment
Influence of the composition containing compound lactobacillus to rat liver inflammation
(1) experimental animal grouping and administration
Male Wistar rat of the weight between 200-225g is chosen, rat is randomly divided into blank group, experimental group, right
According to group, every group of rat takes 20.Blank group is daily stomach-filling physiological saline；Control group is daily stomach-filling physiological saline, and the
Inflammatory reaction is induced using Escherichia coli within 14 days.Experimental group be by embodiment 1-3 and comparative example 1-3 containing compound lactobacillus
Composition is dissolved in physiological saline, configures 100mg/kg stomach-filling liquid, daily every rat oral gavage 5mL, and continuous gavage 14 days.And
Inflammatory reaction is induced using Escherichia coli within 14th day.
(2) rat anti-inflammatory cytokines measure
3 hours after infection, 1mL blood was collected from rat tail vein in the case where no anesthesia.Make blood sample at 4 DEG C
Condensation 30 minutes, then with 1500g centrifugation 15 minutes.By serum collection in PA tube, it is frozen in -20 DEG C.After defrosting, point
Analyse proinflammatory cytokine IL-1 α, the IL-1 β in blood serum sample, IL-6, IFN-γ and tumor necrosis factor (TNF)-α.
Wherein, rat proinflammatory cytokine IL-1 α, IL-1 β, IL-6 measurement result is as shown in table 3, rat proinflammatory cytokines because
Sub- IFN-γ and TNF-α measurement result are as shown in table 4.
Table 3
| Group | n | IL-1α | IL-1β | IL-6 |
| Blank group | 20 | 84.4±7.4 | 309.5±67.1 | 2023±567 |
| Control group | 20 | 313.3±57.6 | 11149.8±3340.3 | 75640±23084 |
| Embodiment 1 | 20 | 198.6±48.7 | 6902.1±1996.2 | 35984±8012 |
| Embodiment 2 | 20 | 163.7±31.9 | 5416.0±2018.1 | 20592±7744 |
| Embodiment 3 | 20 | 179.2±48.1 | 5739.4±2478.0 | 29830±7561 |
| Comparative example 1 | 20 | 330.6±49.1 | 11040.4±3301.7 | 75480±24275 |
| Comparative example 2 | 20 | 303.3±42.4 | 11212.5±3252.2 | 75370±23541 |
| Comparative example 3 | 20 | 311.9±55.2 | 11136.7±3524.3 | 75550±22190 |
Table 4
By table 3 and table 4 it is found that rat blood serum proinflammatory cytokine IL-1 α, IL-1 β of the embodiment 1 into embodiment 3,
The measured value of IL-6, IFN-γ and TNF-α is than comparative example 1 to 3 groups of comparative example, and measurements in embodiment 2 low with control group
Value is even more that significant difference (P < 0.05) is presented with control group, illustrates that the composition of the invention containing compound lactobacillus can be controlled effectively
Treat intestinal inflammatory.
Intervention effect (1) experimental animal of composition containing compound lactobacillus to BALB/c mouse chronic alcohol liver injury
Grouping and administration
BALB/c experiment mice is randomly divided into blank group, alcohol control group and experimental group.Experimental group includes embodiment 1-3
Group and comparative example 1-3 group.Alcohol control group and experimental group are all made of graded ethanol stomach-filling 6 weeks, and (preceding surrounding stomach-filling amount is 2.4g/
Kg/day increases to 4g/kg/day in latter two weeks) chronic alcohol liver injury model is established, in addition, the implementation that experimental group is also given
The composition containing compound lactobacillus in example 1-3 group and comparative example 1-3 group is dissolved in physiological saline, prepares 75mg/kg stomach-filling liquid
Carry out stomach-filling intervention, the daily stomach-filling 5mL of every mouse.
(2) Biochemical Indices In Serum measures
Mouse blood and hepatic tissue sample are collected after experiment, production hepatic tissue pathology slice detects serum transfer ammonia
Enzyme level and lipid-metabolism are horizontal.
AST (glutamic-oxalacetic transaminease) and ALT (glutamic-pyruvic transaminase) is to be clinically used for two kinds of serodiagnosis main to turn ammonia
Enzyme is two most sensitive indexs for reacting hepatocellular injury, and wherein ALT activity increases prompt acute hepatocellular injury, AST activity
Enhancing then prompts injury of mitochondria, reacts the liver cell extent of damage.The measurement of serum lipid metabolism level includes total cholesterol
(total cholesterol, TC) and triglycerides (triglyceride, TG).
In addition, it is horizontal (T-AOC, GSH, GPx, GST, MDA) also to have investigated detection hepatic tissue oxidation-antioxidation.With 4
DEG C physiological saline is homogenate medium, by liver organization 1：9 homogenate, 4 DEG C, 3000rmp centrifugation 10min after take supernatant, by South China
Total antioxidant capacity (total in the detection sample of step described in bio-engineering corporation's LDH, AST, MDA, GSH kit is built up in capital
Anti-oxidation capacity, T-AOC), Antioxidant Indexes GSH, GPx, GST and Lipid peroxidation index MDA.
The results are shown in Table 5 for two kinds of serum aminotransferase determinations of mouse, and serum lipid metabolism is horizontal as shown in table 6, liver group
It is as shown in table 7 to knit oxidation index.
Table 5
| Group | n | AST activity (U/L) | ALT activity (U/L) |
| Blank group | 8 | 59.66±3.14 | 26.39±3.14 |
| Alcohol control group | 8 | 118.25±9.87 | 82.58±10.08 |
| Embodiment 1 | 8 | 101.28±7.56 | 74.82±9.44 |
| Embodiment 2 | 8 | 76.40±4.06 | 43.44±3.65 |
| Embodiment 3 | 8 | 74.93±8.94 | 46.93±8.04 |
| Comparative example 1 | 8 | 105.09±9.75 | 80.51±10.21 |
| Comparative example 2 | 8 | 103.13±9.24 | 76.94±9.56 |
| Comparative example 3 | 8 | 119.14±10.03 | 81.02±9.79 |
Table 6
Table 7
By table 5 and 6 it is found that mouse AST active measured value of the embodiment 1 into embodiment 3, the active measured value of ALT,
Total cholesterol TC measured value, triglycerides TG measured value are lower with alcohol control group than comparative example 1, comparative example 2, comparative example 3.By
Table 7 it is found that mouse T-AOC, GSH, GPx, the GST of embodiment 1 into embodiment 3 measured value than comparative example 1, comparative example 2,
Comparative example 3 and alcohol control group are high, and the measured value of MDA is lower with control group than comparative example 1, comparative example 2, comparative example 3.Wherein,
The measured value of embodiment 3 is even more that significant difference (P < 0.05) is presented with alcohol control group.It can be seen that taking embodiment 1 to reality
The AST (glutamic-oxalacetic transaminease) and ALT (glutamic-pyruvic transaminase) for applying the mouse of the composition containing compound lactobacillus in example 3 are reduced, explanation
Composition containing compound lactobacillus of the invention can effectively mitigate alcohol-induced hepar damnification, inhibit releasing for serum transaminase
It puts.In addition, Lipid peroxidation index (MDA) reduces, total cholesterol (total cholesterol, TC) and triglycerides
(triglyceride, TG) reduce explanation take containing compound lactobacillus composition of the embodiment 1 into embodiment 3 can improve it is small
Mouse disorders of lipid metabolism, furthermore, the total antioxidant capacity in embodiment each group is also improved.In conclusion taking this hair
Bright composition containing compound lactobacillus can slow down the oxidative damage of hepatic tissue, inhibit the release of serum transaminase, improve mouse
Disorders of lipid metabolism is to shield to alcohol-induced hepatic injury.
The embodiments described above only express several embodiments of the present invention, and the description thereof is more specific and detailed, but simultaneously
Limitations on the scope of the patent of the present invention therefore cannot be interpreted as.It should be pointed out that for those of ordinary skill in the art
For, without departing from the inventive concept of the premise, various modifications and improvements can be made, these belong to guarantor of the invention
Protect range.Therefore, the scope of protection of the patent of the invention shall be subject to the appended claims.
Claims (10)
1. a kind of composition containing compound lactobacillus, which is characterized in that the raw material components including following parts by weight：
Wherein, the compound lactobacillus includes Lactobacillus helveticus, lactobacillus plantarum and bifidobacterium longum.
2. the composition according to claim 1 containing compound lactobacillus, which is characterized in that contain in the compound lactobacillus
Viable count be 2.0 × 1010-1.0×1011CFU/g。
3. the composition according to claim 1 or 2 containing compound lactobacillus, which is characterized in that the prebiotics are selected from low
One or more of Fructooligosaccharides, galactooligosaccharide and lactitol.
4. the composition according to claim 3 containing compound lactobacillus, which is characterized in that the prebiotics are 10-30 weight
Measure the combination of the lactitol of the oligofructose of part, the galactooligosaccharide of 20-40 parts by weight and 15-40 parts by weight.
5. a kind of preparation method of the composition of any of claims 1-4 containing compound lactobacillus, which is characterized in that
Include the following steps：
Each raw material is taken according to corresponding parts by weight；
Other each raw materials in addition to compound lactobacillus are sieved respectively and obtain screening object；
The screening object and compound lactobacillus are mixed.
6. the preparation method of the composition according to claim 5 containing compound lactobacillus, which is characterized in that the sieving is
Referred to 50-70 mesh, interception partial size is less than the screening object of 50-70 mesh.
7. the preparation method of the composition according to claim 6 containing compound lactobacillus, which is characterized in that before sieving,
It further include the drying at 50 DEG C -70 DEG C by other each raw materials in addition to compound lactobacillus, until the moisture content in each raw material is low
In 3%.
8. a kind of food, which is characterized in that including the composition according to any one of claims 1-4 containing compound lactobacillus and
Acceptable auxiliary material on food.
9. food according to claim 8, which is characterized in that the type of the food is lozenge, chewable tablets or solid drink
Material.
10. the composition according to claim 1-4 containing compound lactobacillus is in preparation for preventing and/or treating
Application in the drug of alcoholic liver injury or intestinal inflammatory.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811125513.XA CN108904763A (en) | 2018-09-26 | 2018-09-26 | Composition and its preparation method and application containing compound lactobacillus |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811125513.XA CN108904763A (en) | 2018-09-26 | 2018-09-26 | Composition and its preparation method and application containing compound lactobacillus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108904763A true CN108904763A (en) | 2018-11-30 |
Family
ID=64409248
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811125513.XA Pending CN108904763A (en) | 2018-09-26 | 2018-09-26 | Composition and its preparation method and application containing compound lactobacillus |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108904763A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110226687A (en) * | 2019-06-12 | 2019-09-13 | 宁波依萃健生物科技有限公司 | A kind of relieving alcoholism and protecting liver composition and preparation method |
| CN111481561A (en) * | 2020-05-26 | 2020-08-04 | 云浮市新金山生物科技股份有限公司 | Application of galacto-oligosaccharide in preparation of medicine for preventing and treating chemical liver injury and composition |
| CN111603490A (en) * | 2020-06-30 | 2020-09-01 | 江南大学 | Medicine for preventing and/or treating alcoholic intestinal injury |
| CN111803526A (en) * | 2020-07-22 | 2020-10-23 | 威海凯菲尔生物科技有限公司. | Probiotic formula for preventing diarrhea |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106617091A (en) * | 2016-11-08 | 2017-05-10 | 广东正当年生物科技有限公司 | Probiotics and prebiotic compound preparation |
| CN107496850A (en) * | 2017-10-17 | 2017-12-22 | 房学迅 | A kind of formula for adjusting enteral microecological formulation and application |
| CN107647234A (en) * | 2017-08-25 | 2018-02-02 | 善恩康生物科技（苏州）有限公司 | A kind of Ms probiotics solid beverage |
| CN107874251A (en) * | 2017-11-14 | 2018-04-06 | 广东健来福云健康科技股份有限公司 | A kind of eight delicacies probiotic composition with strengthening the spleen and stomach benefit function of intestinal canal |
-
2018
- 2018-09-26 CN CN201811125513.XA patent/CN108904763A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106617091A (en) * | 2016-11-08 | 2017-05-10 | 广东正当年生物科技有限公司 | Probiotics and prebiotic compound preparation |
| CN107647234A (en) * | 2017-08-25 | 2018-02-02 | 善恩康生物科技（苏州）有限公司 | A kind of Ms probiotics solid beverage |
| CN107496850A (en) * | 2017-10-17 | 2017-12-22 | 房学迅 | A kind of formula for adjusting enteral microecological formulation and application |
| CN107874251A (en) * | 2017-11-14 | 2018-04-06 | 广东健来福云健康科技股份有限公司 | A kind of eight delicacies probiotic composition with strengthening the spleen and stomach benefit function of intestinal canal |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110226687A (en) * | 2019-06-12 | 2019-09-13 | 宁波依萃健生物科技有限公司 | A kind of relieving alcoholism and protecting liver composition and preparation method |
| CN111481561A (en) * | 2020-05-26 | 2020-08-04 | 云浮市新金山生物科技股份有限公司 | Application of galacto-oligosaccharide in preparation of medicine for preventing and treating chemical liver injury and composition |
| CN111603490A (en) * | 2020-06-30 | 2020-09-01 | 江南大学 | Medicine for preventing and/or treating alcoholic intestinal injury |
| CN111803526A (en) * | 2020-07-22 | 2020-10-23 | 威海凯菲尔生物科技有限公司. | Probiotic formula for preventing diarrhea |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108004189B (en) | Composite probiotic lactic acid bacteria powder and preparation method and application thereof | |
| CN108904763A (en) | Composition and its preparation method and application containing compound lactobacillus | |
| TWI463986B (en) | New use of lactobacillus plantarum cmu995 strain | |
| CN109125525B (en) | Composition for preventing and treating cardiovascular diseases and preparation method and application thereof | |
| CN111213885A (en) | Probiotic composition with blood fat regulating effect and preparation method and application thereof | |
| CN111011856A (en) | Composition for relieving gastropathy, preparation method thereof and food for relieving gastropathy | |
| CN105685970A (en) | Compound nutritious food capable of improving whole digestive tract | |
| KR20210063728A (en) | Fermented kiwi powder for improving bowel function and method of preparing the same | |
| CN108402371A (en) | A kind of prebiotic compositions that suitable person in middle and old age's constipation crowd takes | |
| EP3861866A1 (en) | Composition comprising molokhia extract as active ingredient for improving gut microbiome or for alleviating, preventing, or treating intestinal inflammation, leaky gut syndrome, obesity, or metabolic disease | |
| CN105802876B (en) | A kind of composite probiotics ferment clover tender shoots powder preparation and its preparation method and application | |
| CN114287633A (en) | Probiotic composition containing cranberry and application of probiotic composition in resisting helicobacter pylori | |
| CN117070426B (en) | Probiotic agent for improving alcoholic fatty liver disease and application thereof | |
| CN114452308A (en) | Probiotics protective agent, microecological preparation prepared from same and application of probiotics protective agent | |
| CN116855413B (en) | Bioactive substance for regulating human body microecological balance prepared from lactobacillus rhamnosus YSs069 and application thereof | |
| CN116172997B (en) | Application of phenyllactic acid in inhibiting helicobacter pylori infection | |
| CN114540257B (en) | Lactobacillus crispatus IOB901 and application thereof in aspects of reducing blood sugar and blood fat | |
| CN114933984B (en) | Probiotic and prebiotic composite composition for promoting in-vivo plasticizer and heavy metal discharge and preparation method thereof | |
| CN114344341B (en) | Composite probiotic composition with intestinal tract regulating effect and preparation method and application thereof | |
| CN109481540A (en) | Composition and its preparation method and application for preventing and treating mammitis of animal | |
| CN111713666A (en) | Fat reducing composition and preparation method thereof | |
| CN116004475B (en) | Lactobacillus plantarum for preventing and assisting in treating stomach deficiency-cold and application thereof | |
| CN108851071A (en) | Sea-buckthorn VP alimentation composition and its preparation method and application | |
| CN116478874B (en) | Lactobacillus paracasei for improving chronic low-grade inflammation and application thereof | |
| CN116606761B (en) | Bifidobacterium animalis subspecies BLa19 capable of relieving rheumatoid arthritis and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20181130 |